June 7, 2022
Damon R. Race, President & CEO
RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood diseases and disorders, today announced the award of a $250,000 Strategic Research Loan (SRL) from the North Carolina Biotechnology Center (NCBC).
GeneVentiv’s lead program, GENV-HEM, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of Hemophilia A or B patients with or without inhibitors. “The Strategic Research Loan from the North Carolina Biotechnology Center enables GeneVentiv to complete significant pre-clinical studies in preparation for an investigational new drug (IND) application and human clinical trials,” commented Damon Race, CEO of GeneVentiv Therapeutics.
“This funding from the NC Biotechnology Center adds to our momentum. In the past six months we’ve received Orphan Drug Designation, added a second gene therapy for hemophilia arthropathy, earned the support of the National Hemophilia Foundation and won a UNC KickStart Commercialization grant,” said Damon Race. “The North Carolina Biotechnology Center conducts rigorous due diligence and receiving this award represents another point of external validation for our lead program.”
About GeneVentiv Therapeutics:
GeneVentiv Therapeutics is a pre-clinical gene therapy company focused on blood diseases and disorders. Our lead program, GENV-HEM, is the first universal gene therapy treatment for Hemophilia A and B with or without inhibitors. GENV-HEM has received Orphan Drug Designation from the FDA and a Letter of Support from the National Hemophilia Foundation. GeneVentiv is advancing an additional gene therapy for Hemophilia Arthropathy, a degenerative joint disease afflicting roughly 50% of patients with hemophilia.